Compendium of Cancer Genome Aberrations

HAEM5:Volunteer Assignments and Opportunities: Difference between revisions

[unchecked revision][checked revision]
← Older edit
VisualWikitext
No edit summary
No edit summary
 
(218 intermediate revisions by 11 users not shown)
Line 1: Line 1:
{| class="wikitable" style="margin:auto"
Ian Welcome!
|+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition) Content
 
'''A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated in 2024; we're aligning the related CCGA content to the new structure.'''
 
*For assignments, please see the "Author" column below (highlighted blue).
 
*If empty (no name is present), please volunteer to create content for that disease!
*If "PENDING" is present, the original author of that disease page is currently being contacted about revising the content.
 
*To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.
*Note - "NEW (No Prior)" in the 4th edition columns means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content previously added.
 
__TOC__
 
<br />
{| class="wikitable sortable" style="margin:auto"
|+<big>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (5th Edition) Content</big>
|-
|-
!Disease (5th Edition)!!Page Type!!Author (5th edition)!!Date Assigned to Author (5th Edition)!!Target Completion Date (5th Edition)!!Content Status (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review!!Notes
!Disease (5th Edition)!!Page Type!!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)!!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)!!Content Status (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review (5th Edition)!!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS)
|
====CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS)====
|
|
----<br />
----<br />
Line 12: Line 32:
----<br />
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
----<br />
|
|
----<br />
|
|
|-
----<br />
|Clonal haematopoiesis||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| ||
|
|
----<br />
|
|
----<br />
|-
|[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease||Meenakshi Mehrotra
|4/8/24, email again in 9/29/25; Meenakshi confirmed om 9/30/25.
| ||Pending|| ||Fabiola Quintero-Rivera (FQR)|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Clonal cytopenias of undetermined significance||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Clonal cytopenias of undetermined significance|Clonal cytopenias of undetermined significance]]||Disease||Zejuan Li
|
|10/3/2025
|
| ||Pending|| ||FQR|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Chronic myeloid leukaemia||Disease||Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||FQR|| ||
|[[HAEM5:Chronic myeloid leukaemia|Chronic myeloid leukaemia]]||Disease||J . Reid||9/29/25|| || || ||FQR|| ||
|
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
|Complete
|Date page was created
|
|
|-
|-
|Chronic neutrophilic leukaemia||Disease||Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally|| || || || ||FQR|| ||
|[[HAEM5:Chronic neutrophilic leukaemia|Chronic neutrophilic leukaemia]]||Disease||PENDING
|
| || || || ||FQR|| ||
|Chronic Neutrophilic Leukemia (CNL)
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
|Complete
|Date page was created
|
|
|-
|-
|Chronic eosinophilic leukaemia||Disease||Chelsea D. Kramish; Daynna J.Wolff Pending Review*|| || || || ||FQR|| ||
|[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease||Daynna Wolff
|10/14/25|| || || ||FQR|| ||
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
|Chelsea D. Kramish; Daynna J.Wolff
|complete/pending faculty review
|
|
|
|
|-
|-
|Polycythaemia vera||Disease||Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center|| || || || ||FQR|| ||
|[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease||
| || || || ||FQR|| ||
|Polycythemia Vera (PV)
|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
|Complete
|
|
|
|
|-
|-
|Essential thrombocythaemia||Disease||Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN|| || || || ||FQR|| ||
|[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease||Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
|10/1/25|| ||Pending|| ||FQR|| ||
|Essential Thrombocythemia (ET)
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
|Complete
|
|
|
|
|-
|-
|Primary myelofibrosis||Disease||T. Niroshi Senaratne, UCLA|| || || || ||FQR|| ||
|[[HAEM5:Primary myelofibrosis|Primary myelofibrosis]]||Disease||PENDING
|
| || || || ||FQR|| ||
|Primary Myelofibrosis (PMF)
|T. Niroshi Senaratne, UCLA
|Complete
|8/4/2020 before submission<br />
|
|
|-
|-
|Juvenile myelomonocytic leukaemia||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |Assistant Professor, Pathology Associate Director | Division of Molecular Pathology, Genetics and Genomics Duke University Health System Clinical Laboratories|| || || || ||FQR|| ||
|[[HAEM5:Juvenile myelomonocytic leukaemia|Juvenile myelomonocytic leukaemia]]||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |PENDING
|
| || || || ||FQR|| ||
|Juvenile Myelomonocytic Leukemia (JMML)
|<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki>
 
Associate Director | Division of Molecular Pathology, Genetics and Genomics
 
Duke University Health System Clinical Laboratories
|PENDING importing content and reference formatting
|
|
|FQR has emailed SR several times, last 4/20/22
|-
|-
|Myeloproliferative neoplasm, NOS||Disease||Thomas Lee, MD, PhD, University of California, Los Angeles|| || || || ||FQR|| ||
!Disease (5th Edition)
|
!Page Type
|
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|Cutaneous mastocytosis||Disease||S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD|| || || || ||FQR|| ||
|[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease||PENDING
| || || || ||FQR|| ||
|Myeloproliferative Neoplasm (MPN), Unclassifiable
|Thomas Lee, MD, PhD, University of California, Los Angeles
|Complete
|
|
|
|
|-
|-
|Systemic mastocytosis||Disease||'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University  '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University|| || || || ||FQR|| ||
|[[HAEM5:Cutaneous mastocytosis|Cutaneous mastocytosis]]||Disease||PENDING
| || || || ||FQR|| ||
|Cutaneous Mastocytosis
|S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD
|Complete
|
|
|
|
|-
|-
|Mast cell sarcoma||Disease||Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL|| || || || ||FQR|| ||
|[[HAEM5:Systemic mastocytosis|Systemic mastocytosis]]||Disease||PENDING|| || || || ||FQR|| ||
|Systemic Mastocytosis
|Abdullah Osme, MD, University Hospitals Cleveland Medical Center, Case Western Reserve University  Shashi Shetty, Ph.D. FACMG, FCCMG, University Hospitals Cleveland Medical Center, Case Western Reserve University
|Complete
|
|
|
|
|-
|-
|Myelodysplastic neoplasm with low blasts and 5q deletion||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Mast cell sarcoma|Mast cell sarcoma]]||Disease||PENDING
| || || || ||FQR|| ||
|Mast Cell Sarcoma
|Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL
|Complete
|
|
|
|
|-
|-
|Myelodysplastic neoplasm with low blasts and SF3B1 mutation||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic neoplasm with low blasts and 5q deletion|Myelodysplastic neoplasm with low blasts and 5q deletion]]||Disease||PENDING
| || || || ||FQR|| ||
|Myelodysplastic Syndrome (MDS) with Isolated del(5q)
|Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG
|Complete
|
|
|
|
|-
|-
|Myelodysplastic neoplasm with biallelic TP53 inactivation||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic neoplasm with low blasts and SF3B1 mutation|Myelodysplastic neoplasm with low blasts and SF3B1 mutation]]||Disease||
|
| || || || ||FQR|| ||
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Myelodysplastic neoplasm with biallelic TP53 inactivation|Myelodysplastic neoplasm with biallelic TP53 inactivation]]||Disease||Eric McGinnis (assigned to new 5th edition page - FQR is this reviewed?) YES fqr 9/29/25|| || || || ||FQR|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic neoplasm with low blasts|Myelodysplastic neoplasm with low blasts]]||Disease|| || || || || ||FQR|| ||
|
|NEW (No Prior)
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Myelodysplastic neoplasm, hypoplastic||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic neoplasm, hypoplastic|Myelodysplastic neoplasm, hypoplastic]]||Disease|| || || || || ||FQR|| ||
|
|NEW (No Prior)
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic neoplasm with increased blasts|Myelodysplastic neoplasm with increased blasts]]||Disease||PENDING
| || || || ||FQR|| ||
|Myelodysplastic Syndrome (MDS) with Excess Blasts
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
|Complete
|
|
|
|
|-
|-
|Childhood myelodysplastic neoplasm with low blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
!Disease (5th Edition)
|
!Page Type
|
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|Childhood myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
|[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease||PENDING
| || || || ||FQR|| ||
|Refractory Cytopenia of Childhood
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
|Complete
|
|
|
|
|-
|-
|Chronic myelomonocytic leukaemia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| ||
|[[HAEM5:Childhood myelodysplastic neoplasm with increased blasts|Childhood myelodysplastic neoplasm with increased blasts]]||Disease||PENDING
| || || || ||FQR|| ||
|Refractory Cytopenia of Childhood
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
|Complete
|
|
|
|
|-
|-
|Myelodysplastic/myeloproliferative neoplasm with neutrophilia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| ||
|[[HAEM5:Chronic myelomonocytic leukaemia|Chronic myelomonocytic leukaemia]]||Disease||PENDING
| || || || ||FQR|| ||
|Chronic Myelomonocytic Leukemia (CMML)
|Linsheng Zhang, MD, PhD
|Complete
|
|
|
|
|-
|-
|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis||Disease||Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine|| || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with neutrophilia|Myelodysplastic/myeloproliferative neoplasm with neutrophilia]]||Disease||PENDING
| || || || ||FQR|| ||
|Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative
|Linsheng Zhang, MD, PhD
|Complete
|
|
|
|
|-
|-
|Myelodysplastic/myeloproliferative neoplasm, NOS||Disease||Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia|| || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis]]||Disease||PENDING
|
| || || || ||FQR|| ||
|Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)
|Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine
|Complete
|Date page was created
|
|
|-
|-
|Myeloid/lymphoid neoplasm with PDGFRA rearrangement||Disease||Jay Alden, DO|| || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease||
| || || || ||FQR|| ||
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable
|Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia
|Complete
|
|
|
|
|-
|-
|Myeloid/lymphoid neoplasm with PDGFRB rearrangement||Disease||Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD|| || || || ||FQR|| ||
|[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]]
|Disease
|Rabail Aslam, MD (trainee);
Shashi Shetty, Ph.D.
|7/1/24
|
|
|Pending
|
|
|-
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
|Myeloid/lymphoid neoplasm with FGFR1 rearrangement||Disease||Yanna Ding, MD PhD|| || || || ||FQR|| ||
|
|
|
|
|-
|Acute Promyelocytic Leukemia (APL) with PML-RARA
|Myeloid/lymphoid neoplasm with JAK2 rearrangement||Disease||Jessica Snider, M.D. and Daynna J. Wolff, PhD|| || || || ||FQR|| ||
|Yiming Zhong, Ph.D., Megan Piazza, Ph.D., and Shashi Shetty, Ph.D.
|
|Complete
|03/01/2021-MS (re-review)
|
|
|-
|-
|Myeloid/lymphoid neoplasm with FLT3 rearrangement||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]]
|Disease
|Mayuri Shende (trainee);
Scott Turner (mentor)<br />
|9/22/24
|
|
|Pending
|
|
|-
|JH_MS
|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion||Disease|| || || || || ||FQR|| ||
|
|
|
|
|-
|Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1
|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes||Disease|| || || || || ||FQR|| ||
|Christine Bryke, MD<br>Beth Israel Deaconess Medical Center, Boston, MA
|
|Complete
|04/26/2021-MS (re-review)
|
|
|-
|-
|Acute promyelocytic leukaemia with PML::RARA fusion
|[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]]
|Disease
|Disease
|Yiming Zhong, Ph.D., Megan Piazza, Ph.D., and Shashi Shetty, Ph.D.
|Mayuri Shende (trainee);
Scott Turner (mentor)<br />
|9/22/24
|
|
|Pending
|
|
|JH_MS
|
|
|
|
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
|Acute Myeloid Leukemia (AML) with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
|
|Christine Bryke, MD <br> Beth Israel Deaconess Medical Center, Boston, MA
|
|Complete
|
|03/01/2021-MS (re-review)
|
|
|-
|-
|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion
|[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]]
|Disease
|Disease
|Christine Bryke, MD<br>Beth Israel Deaconess Medical Center, Boston, MA
|Jennelle C. Hodge, PhD
|
|
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
|
|
|
|
|Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214
|Jennelle C. Hodge, PhD, FACMG
|Complete
|02/24/2021-MS (re-review)
|
|
|
|-
|-
|Acute myeloid leukaemia with CBFB::MYH11 fusion
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]]
|Disease
|Disease
|Christine Bryke, MD <br> Beth Israel Deaconess Medical Center, Boston, MA
|Jennelle C. Hodge, PhD
|
|
|
|
|
|Complete
|
|
|JH_MS
|JH_MS
|
|
|
|
|Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1
|Jennelle C. Hodge, PhD, FACMG
|Complete
|
|
|
|
|-
|-
|Acute myeloid leukaemia with DEK::NUP214 fusion
|[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]]
|Disease
|Disease
|
|Xinxiu Xu (trainee);
|
Malini Sathanoori, Ph.D.
|4/15/25
|
|
|
|
Line 198: Line 399:
|
|
|
|
|Acute Myeloid Leukemia (AML) with BCR-ABL1
|Kay Weng Choy MBBS, Monash Medical Centre
|Complete
|
|
|
|
|-
|-
|Acute myeloid leukaemia with RBM15::MRTFA fusion
|[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]]
|Disease
|Disease
|Jennelle C. Hodge, PhD, FACMG
|Rabail Aslam, MD (trainee);
|
Shashi Shetty, Ph.D.
|
|7/1/24
|
|
|Pending
|
|
|JH_MS
|JH_MS
|
|
|
|
|
|Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3
|Megan Piazza, Ph.D., Yiming Zhong, Ph.D., Shashi Shetty, Ph.D.
|Complete
|03/01/2021-MS (re-review)
|
|
|-
|-
|Acute myeloid leukaemia with BCR::ABL1 fusion
|[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]]
|Disease
|Disease
|Kay Weng Choy MBBS, Monash Medical Centre
|Gordana Raca MD PhD,
|
|9/8/25
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
|
|
|
|
|Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM
|Gordana Raca MD PhD, University of Southern California, Los Angeles
|Complete
|
|
|
|Need permission for figure? Update WHO?
|-
|-
|Acute myeloid leukaemia with KMT2A rearrangement
|[[HAEM5:Acute myeloid leukaemia with NUP98 rearrangement|Acute myeloid leukaemia with NUP98 rearrangement]]
|Disease
|Disease
|Megan Piazza, Ph.D., Yiming Zhong, Ph.D., Shashi Shetty, Ph.D.
|Eric McGinnis, MD;
|
Fatma Al-Bulushi (trannee)
|
|12/20/23
|
|
|Pending
|
|
|JH_MS
|JH_MS
|
|
|
|
|
|NEW (No Prior)
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Acute myeloid leukaemia with MECOM rearrangement
|[[HAEM5:Acute myeloid leukaemia with NPM1 mutation|Acute myeloid leukaemia with NPM1 mutation]]
|Disease
|Disease
|
|
Line 249: Line 464:
|JH_MS
|JH_MS
|
|
|emailed request on 7/16/24. No response as of 9/7/25.
Prior author: Xinjie Xu, PhD, FACMG
Open to new author
|Acute Myeloid Leukemia (AML) with Mutated NPM1
|Xinjie Xu, PhD, FACMG
|Complete
|
|
|
|Add WHO reference<br />
|
|-
|-
|Acute myeloid leukaemia with NUP98 rearrangement
|[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]]
|Disease
|Disease
|
|Xinxiu Xu (trainee);
|
Malini Sathanoori, Ph.D.
|4/15/25
|
|
|
|
Line 263: Line 485:
|
|
|
|
|Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA
|Paul Defazio, MSc, Monash Health
|Complete
|
|
|
|
|-
|-
|Acute myeloid leukaemia with NPM1 mutation
|[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]]
|Disease
|Disease
|Xinjie Xu, PhD, FACMG
|
|
|
|
|
Line 275: Line 500:
|JH_MS
|JH_MS
|
|
|
|emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25
|Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes
|Fei Yang, MD, FACMG  <br> Oregon Health & Science University
|Complete
|
|
|
|
|-
|-
|Acute myeloid leukaemia with CEBPA mutation
|[[HAEM5:Acute myeloid leukaemia with other defined genetic alterations|Acute myeloid leukaemia with other defined genetic alterations]]
|Disease
|Disease
|Paul Defazio, MSc, Monash Health
|
|
|
|
|
Line 289: Line 517:
|
|
|
|
|
|NEW (No Prior)
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Acute myeloid leukaemia, myelodysplasia-related
|[[HAEM5:Acute myeloid leukaemia with minimal differentiation|Acute myeloid leukaemia with minimal differentiation]]
|Disease
|Disease
|Fei Yang, MD, FACMG  <br> Oregon Health & Science University, Portland, OR
|
|
|
|
|
Line 301: Line 532:
|JH_MS
|JH_MS
|
|
|Prior author: Celeste Eno, PhD
Open to new author
|Acute Myeloid Leukemia (AML) with Minimal Differentiation
|Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles,  Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine
|Complete
|
|
|
|
|
|-
|-
|Acute myeloid leukaemia with other defined genetic alterations
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]]
|Disease
|Disease
|Jennelle C. Hodge, PhD
|
|
|
|
|Pending
|
|
|JH_MS
|
|
|
|
|JH_MS
|Acute Myeloid Leukemia (AML) without Maturation
|
|Jennelle C. Hodge, PhD, FACMG
|
|Complete
|
|
|
|
|-
|-
|Acute myeloid leukaemia with minimal differentiation
|[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]]
|Disease
|Disease
|Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles,  Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine
|Jennelle C. Hodge, PhD
|
|
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
|
|
|
|
|Acute Myeloid Leukemia (AML) with Maturation
|Jennelle C. Hodge, PhD, FACMG
|Complete
|
|
|
|
|-
|-
|Acute myeloid leukaemia without maturation
|[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]]
|Disease
|Disease
|Jennelle C. Hodge, PhD, FACMG
|Ashwini Yenamandra PhD FACMG
|
|5/1/24
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
|
|
|
|
|Acute Basophilic Leukemia
|Ashwini Yenamandra PhD FACMG
|Complete
|
|
|
|
|-
|-
|Acute myeloid leukaemia with maturation
|[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]]
|Disease
|Disease
|Jennelle C. Hodge, PhD, FACMG
|
|
|
|
|
Line 353: Line 614:
|JH_MS
|JH_MS
|
|
|
|emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25
|Acute Myelomonocytic Leukemia
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
|Complete
|
|
|
|
|-
|-
|Acute basophilic leukaemia
|[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]]
|Disease
|Disease
|Ashwini Yenamandra PhD FACMG
|
|
|
|
|
Line 366: Line 630:
|JH_MS
|JH_MS
|
|
|
|emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25
|Acute Monoblastic and Monocytic Leukemia
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
|Complete
|
|
|
|
|-
|-
|Acute myelomonocytic leukaemia
|[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]]
|Disease
|Disease
|Fei Yang, MD, FACMG <br> Oregon Health & Science University, Portland, OR
|Ashwini Yenamandra PhD FACMG
|
|5/1/24
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
|
|
|
|
|Pure Erythroid Leukemia
|Ashwini Yenamandra PhD FACMG
|Complete
|
|
|
|
|-
|-
|Acute monocytic leukaemia
|[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]]
|Disease
|Disease
|Fei Yang, MD, FACMG  <br> Oregon Health & Science University, Portland, OR
|
|
|
|
|
Line 392: Line 662:
|JH_MS
|JH_MS
|
|
|
|emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25
|Acute Megakaryoblastic Leukemia (AMKL)
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
|Complete
|
|
|
|
|-
|-
|Acute erythroid leukaemia
|[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]]
|Disease
|Disease
|Ashwini Yenamandra PhD FACMG
|Yalda Naeini
|6/11/24
|
|
|Pending
|
|
|JH_MS
|
|
|
|
|JH_MS
|Myeloid Sarcoma
|Yalda Naeini, MD, School of Medicine at University of California Los Angeles Fabiola Quintero-Rivera, MD, FACMG, School of Medicine at University of California Irvine
|Complete
|
|
|-
|RESOLVE 4th edition AML-Related NON-WHO entities content
|[[HAEM4:Acute Myeloid Leukemia (AML) with Mutated FLT3|Acute Myeloid Leukemia (AML) with Mutated FLT3]] + [[HAEM4:Acute Myeloid Leukemia (AML) with NUP214-ABL1|Acute Myeloid Leukemia (AML) with NUP214-ABL1]] + [[HAEM4:Acute Myeloid Leukemia (AML) with t(4;12)(q12;p13); CHIC2-ETV6|Acute Myeloid Leukemia (AML) with t(4;12)(q12;p13); CHIC2-ETV6]]
|ISSUE- FIX
 
 
Resolve Non-WHO entities
|
|
|
|
|
|
|
|
|-
|Acute megakaryoblastic leukaemia
|Disease
|Fei Yang, MD, FACMG  <br> Oregon Health & Science University, Portland, OR
|
|
|
|
|
|
|
|
|JH_MS
|
|
|
|
Line 422: Line 704:
|
|
|-
|-
|Myeloid sarcoma
|[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]]
|Disease
|Disease
|Yalda Naeini, MD, School of Medicine at University of California Los Angeles Fabiola Quintero-Rivera, MD, FACMG, School of Medicine at University of California Irvine
|Rabail Aslam, MD (trainee);
|
Shashi Shetty, Ph.D.
|
|7/1/24
|
|
|Pending
|
|
|JH_MS
|JH_MS
|
|
|
|
|Therapy-Related Myeloid Neoplasms
|Shawn A. Silver, DO, Shashi Shetty, Ph.D.
|Complete
|
|
|
|Check reference format
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|Myeloid neoplasm post cytotoxic therapy
|[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]]
|Disease
|Disease
|Shawn A. Silver, DO, Shashi Shetty, Ph.D.
|Malini Sathanoori, Ph.D.
|
|12/6/24
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
|
|
|
|
|
|Multiple pages including overview page ([[Myeloid Neoplasms with Germline Predisposition|Myeloid Neoplasms with Germline Predisposition - Compendium of Cancer Genome Aberrations (ccga.io)]]) and 6 disease pages ( [[HAEM4:Acute Myeloid Leukaemia with Germline CEBPA Mutation]], [[HAEM4:Myeloid Neoplasms with Germline DDX41 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline ETV6 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline GATA2 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline RUNX1 Mutation]], [[HAEM4:Myeloid Neoplasms with Germline ANKRD26 Mutation]])
|
|See links from instructions on the 5th edition page
|Complete
|Most were re-reviewed by MS on 03/02/2021
|For page Acute Myeloid Leukaemia with Germline CEBPA Mutation - Note by MS of "Review completed, awaiting some clarification from JH - 07/04/2022"
|-
|-
|Myeloid neoplasms associated with germline predisposition
|[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]]
|Disease
|Disease
|
|
Line 457: Line 762:
|JH_MS
|JH_MS
|
|
|
|Prior author:
Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO
|MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome  +  Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome
|Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO
|Complete (all three pages)
|
|
|
|
|-
|-
|Myeloid proliferations associated with Down syndrome
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRA rearrangement|Myeloid/lymphoid neoplasm with PDGFRA rearrangement]]
|Disease
|Disease
|Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO
|PENDING
|
|
|
|
|
|
|
|
|JH_MS
|FQR
|
|
|
|
|Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement
|Jay Alden, DO
|Complete
|
|
|
|
|-
|-
|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRB rearrangement|Myeloid/lymphoid neoplasm with PDGFRB rearrangement]]
|Disease
|Disease
|Tracy Tucker, PhD, FCCMG
|PENDING
|
|
|
|
|
|
|
|
|JH_MS
|FQR
|
|
|
|
|Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement
|Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD
|Complete
|
|
|
|
|-
|-
|Mixed-phenotype acute leukaemia with KMT2A rearrangement
|[[HAEM5:Myeloid/lymphoid neoplasm with FGFR1 rearrangement|Myeloid/lymphoid neoplasm with FGFR1 rearrangement]]
|Disease
|Disease
|Tracy Tucker, PhD, FCCMG
|PENDING
|
|
|
|
|
|
|
|
|JH_MS
|FQR
|
|
|
|
|Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
|Yanna Ding, MD PhD
|Complete
|
|
|
|
|-
|-
|Acute leukaemia of ambiguous lineage with other defined genetic alterations
|[[HAEM5:Myeloid/lymphoid neoplasm with JAK2 rearrangement|Myeloid/lymphoid neoplasm with JAK2 rearrangement]]
|Disease
|Disease
|ISSUE- FIX
Resolve Non-WHO entities
|
|
|
|
|
|
|
|
|
|FQR
|JH_MS
|
|
|
|
|Myeloid/Lymphoid Neoplasms with PCM1-JAK2 + consider a non-WHO page Myeloid/Lymphoid Neoplasms with ETV6-JAK2 ([[HAEM4:Myeloid/Lymphoid Neoplasms with ETV6-JAK2|Myeloid/Lymphoid Neoplasms with ETV6-JAK2 - Compendium of Cancer Genome Aberrations (ccga.io)]])  + another non-WHO page Myeloid/Lymphoid Neoplasms with BCR-JAK2 ([[HAEM4:Myeloid/Lymphoid Neoplasms with BCR-JAK2|Myeloid/Lymphoid Neoplasms with BCR-JAK2 - Compendium of Cancer Genome Aberrations (ccga.io)]] )  - both non-WHO pages are authored by trainee Lauren Crowson-Hindman and Daynna Wolff
|Jessica Snider, M.D. and Daynna J. Wolff, PhD + non-WHO pages by trainee Lauren Crowson-Hindman and Daynna Wolff
|Complete
|
|
|
|
|-
|-
|Mixed-phenotype acute leukaemia, B/myeloid
|[[HAEM5:Myeloid/lymphoid neoplasm with FLT3 rearrangement|Myeloid/lymphoid neoplasm with FLT3 rearrangement]]
|Disease
|Disease
|Priyatharsini Nirmalanantham, MD and  Shashi Shetty, PhD
|
|
|
|
|
|
|
|JH_MS
|
|
|
|
|FQR
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Mixed-phenotype acute leukaemia, T/myeloid
|[[HAEM5:Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion]]
|Disease
|Disease
|Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine
|Mayuri Shende (trainee);
Scott Turner (mentor)<br />
|9/22/24
|
|
|Pending
|
|
|FQR
|
|
|
|
|JH_MS
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes]]
|Disease
|Rolando Garcia
|2/7/2025
|
|
|Pending
|
|
|FQR
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Mixed-phenotype acute leukaemia, rare types
|[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]]
|Disease
|Disease
|Elicia Goodale, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina
|Tracy Tucker, PhD, FCCMG
|
|4/6/24
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
|
|
|
|
|Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1
|Tracy Tucker, PhD, FCCMG
|Complete
|
|
|
|
|-
|-
|Acute leukaemia of ambiguous lineage, NOS
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]]
|Disease
|Disease
|Tracy Tucker, PhD, FCCMG
|4/6/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
|
|
|
|
|Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged
|Tracy Tucker, PhD, FCCMG
|Complete
|
|
|
|
|-
|-
|Acute undifferentiated leukaemia
|[[HAEM5:Acute leukaemia of ambiguous lineage with other defined genetic alterations|Acute leukaemia of ambiguous lineage with other defined genetic alterations]]
|Disease
|Disease
|Amelia Nakanishi, MD and Shashi Shetty, PhD
|
|
|
|
|
Line 575: Line 944:
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]]
|Disease
|Rabail Aslam, MD (trainee);
Shashi Shetty, Ph.D.
|7/1/24
|
|
|Pending
|
|
|-
|JH_MS
|CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS)
|
|
----<br />
|
|
----<br />
|Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified
|Priyatharsini Nirmalanantham, MD and  Shashi Shetty, PhD
|Complete
|
|
|
|
|-
|[[HAEM5:Mixed-phenotype acute leukaemia, T/myeloid|Mixed-phenotype acute leukaemia, T/myeloid]]
|Disease
|PENDING
|
|
|
|
|
|
|
|
|JH_MS
|
|
|emailed 5/1/24
|Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified
|Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine
|Complete
|
|
|
|
|-
|-
|Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm
|[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]]
|Disease
|Disease
|Daynna Wolff, PhD
|5/9/24
|
|
|Pending
|
|
|JH_MS
|
|
|
|
|
|Mixed-Phenotype Acute Leukemia, Not Otherwise Specified (NOS), Rare Types
|Greg Corboy (GC)
|Elicia Goodale, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina
|
|PENDING
|
|
|
|
|
|-
|-
|Blastic plasmacytoid dendritic cell neoplasm
|[[HAEM5:Acute leukaemia of ambiguous lineage, NOS|Acute leukaemia of ambiguous lineage, NOS]]
|Disease
|Disease
|Hao Liu, MD and Daynna J. Wolff, PhD
|
|
|
|
|
|
|
|GC
|
|
|
|
|JH_MS
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Langerhans cell histiocytosis
|[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]]
|Disease
|Disease
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|Rabail Aslam, MD (trainee);
Shashi Shetty, Ph.D.
|7/1/24
|
|
|Pending
|
|
|JH_MS
|
|
|
|
|GC
|Acute Undifferentiated Leukemia
|Amelia Nakanishi, MD and Shashi Shetty, PhD
|Complete
|
|
|Check reference format
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|
|
====CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS)====
|
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
----<br />
|
|
|-
----<br />
|Langerhans cell sarcoma
|Disease
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
|GC
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|-
|-
|Indeterminate dendritic cell tumour
|[[HAEM5:Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm|Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm]]
|Disease
|Disease
|
|
Line 651: Line 1,085:
|
|
|
|
|
|Greg Corboy (GC)
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]]
|Disease
|Daynna Wolff
|5/3/2025
|8/3/2025
|Pending
|
|
|GC
|GC
|
|
|
|
|Blastic Plasmacytoid Dendritic Cell Neoplasm
|Hao Liu, MD and Daynna J. Wolff, PhD
|Complete
|
|
|
|Previously within myeloid section under JH/MS editors
|-
|-
|Interdigitating dendritic cell sarcoma
|[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]]
|Disease
|Disease
|
|
Line 668: Line 1,121:
|
|
|
|
|
|Langerhans Cell Histiocytosis
|
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|Complete
|5/19/2022 Emailed 5/6/2025, no reply<br />
|Date completed by author: 04/28/2022
|-
|-
|Juvenile xanthogranuloma
|[[HAEM5:Langerhans cell sarcoma|Langerhans cell sarcoma]]
|Disease
|Disease
|
|
Line 681: Line 1,137:
|
|
|
|
|
|Langerhans Cell Sarcoma
|
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|Complete
|5/19/2022 Emailed 5/6/2025, no reply<br />
|Date completed by author: 04/28/2022
|-
|-
|Erdheim-Chester disease
|[[HAEM5:Indeterminate dendritic cell tumour|Indeterminate dendritic cell tumour]]
|Disease
|Disease
|
|
Line 694: Line 1,153:
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Interdigitating dendritic cell sarcoma|Interdigitating dendritic cell sarcoma]]
|Disease
|Muhammad Zulfiqar, MD
|7/4/2025
|10/4/2025
|Pending
|
|
|GC
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Rosai-Dorfman Disease
|[[HAEM5:Juvenile xanthogranuloma|Juvenile xanthogranuloma]]
|Disease
|Disease
|Mayuri Shende (trainee);
Scott Turner (mentor)<br />
|9/22/24
|12/22/24 Emailed 9/4/2025 to remind
|Pending
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Erdheim-Chester disease|Erdheim-Chester disease]]
|Disease
|Mayuri Shende (trainee);
Scott Turner (mentor)<br />
|9/22/24
|12/22/24 Emailed 9/4/2025 to remind
|Pending
|
|
|GC
|
|
|GC
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Rosai-Dorfman Disease|Rosai-Dorfman Disease]]
|Disease
|Mayuri Shende (trainee);
Scott Turner (mentor)<br />
|9/22/24
|12/22/24 Emailed 9/4/2025 to remind
|Pending
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|ALK-positive histiocytosis
|[[HAEM5:ALK-positive histiocytosis|ALK-positive histiocytosis]]
|Disease
|Disease
|
|
Line 720: Line 1,236:
|
|
|
|
|
|NEW (No Prior)
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Histiocytic sarcoma
|[[HAEM5:Histiocytic sarcoma|Histiocytic sarcoma]]
|Disease
|Disease
|Marie-France Gagnon, MD, Mayo Clinic, Xinjie Xu, PhD FACMG, Mayo Clinic
|
|
|
|
|
Line 733: Line 1,252:
|
|
|
|
|Histiocytic Sarcoma
|Marie-France Gagnon, MD, Mayo Clinic, Xinjie Xu, PhD FACMG, Mayo Clinic
|Complete
|10/01/2021
|Date completed by author: 10/01/2021. Emailed both authors 5/1/2025, no reply.
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|
====CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)====
|
----<br />
|
|
----<br />
|
|
|-
----<br />
|CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
|
|
----<br />
----<br />
Line 742: Line 1,287:
----<br />
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|-
|-
|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma
|[[HAEM5:Reactive B-cell rich lymphoid proliferations that can mimic lymphoma|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma]]
|Disease
|Disease
|Muhammad Zulfiqar, MD
|7/4/2025
|10/4/2025 Emailed 9/4/2025 to remind
|Pending
|
|
|GC
|
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:IgG4-related disease|IgG4-related disease]]
|Disease
|Muhammad Zulfiqar, MD
|7/4/2025
|10/4/2025 Emailed 9/4/2025 to remind
|Pending
|
|
|GC
|GC
|
|
|
|
|
|NEW (No Prior)
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|IgG4-related disease
|[[HAEM5:Unicentric Castleman disease|Unicentric Castleman disease]]
|Disease
|Disease
|
|
Line 774: Line 1,347:
|
|
|
|
|
|NEW (No Prior)
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Unicentric Castleman disease
|[[HAEM5:Idiopathic multicentric Castleman disease|Idiopathic multicentric Castleman disease]]
|Disease
|Disease
|
|
Line 787: Line 1,363:
|
|
|
|
|
|NEW (No Prior)
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Idiopathic multicentric Castleman disease
|[[HAEM5:KSHV/HHV8-associated multicentric Castleman disease|KSHV/HHV8-associated multicentric Castleman disease]]
|Disease
|Disease
|
|
Line 800: Line 1,379:
|
|
|
|
|
|Multicentric Castleman Disease
|
|Sudha Arumugam, MD
|Complete
|01/24/2022. Emailed 5/1/2025, no response
|Date completed by author: 01/24/2022
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|KSHV/HHV8-associated multicentric Castleman disease
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]]
|Disease
|Disease
|Sudha Arumugam, MD
|To be covered in B-ALL, NOS
|
|
|
|
|
|
|
|
|GC
|Sumi Kitahara (SK)
|
|
|
|
|B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified
|Holli Drendel
|PENDING
|
|
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]]
|Disease
|Disease
|Miguel Gonzalez Mancera, MD
|
|
|
|
|Complete (pending review by SK)
|
|
|SK
|
|
|
|
|Holli Drendel (HD)
|B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy
|
|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG
|
|PENDING
|
|
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]]
|Disease
|Disease
|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG
|Miguel Gonzalez Mancera, MD
|
|
|
|
|Complete (pending review by SK)
|
|
|
|SK
|HD
|
|
|
|
|B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy
|Ashwini Yenamandra PhD FACMG  Lisa Smith PhD FACMG  Yassmine Akkari PhD FACMG
|Complete
|
|
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma with hypodiploidy
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]]
|Disease
|Disease
|Ashwini Yenamandra PhD FACMG  Lisa Smith PhD FACMG  Yassmine Akkari PhD FACMG
|Holli Drendel, PhD
|Nov 11/2025
|
|
|Pending
|
|
|SK
|
|
|
|
|HD
|B-Lymphoblastic Leukemia/Lymphoma with iAMP21 [but was completed as a 5th edition page by Holli]
|
|Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte
|
|?Complete
|
|
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma with iAMP21
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]]
|Disease
|Disease
|Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte
|Karin Miller, MD
|10/9/2025
|12/5/2025
|
|
|
|
|SK
|
|
|
|
|HD
|B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1
|
|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG
|
|PENDING
|
|
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]]
|Disease
|Disease
|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG
|Mark G. Evans, MD
|10/1/2025
|11/17/2025
|Complete (pending review by SK)
|11/8/2025
|SK
|Pending
|
|
|B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like
|Mark G. Evans, MD, University of California, Irvine  Fabiola Quintero-Rivera, MD, University of California, Irvine
|Complete
|
|
|
|
|-
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]]
|Disease
|Gokce A. Toruner, MD, PhD
|10/9/2025
|11/5/2025
|Pending
|
|
|HD
|SK
|
|
|
|
|B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged
|Yassmine Akkari  Nicolas Millan
|PENDING
|
|
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]]
|Disease
|Disease
|Mark G. Evans, MD, University of California, Irvine  Fabiola Quintero-Rivera, MD, University of California, Irvine
|Gokce A. Toruner, MD, PhD
|10/8/2025
|12/1/2025
|Pending
|
|
|SK
|
|
|
|
|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion
|Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG  Cancer Category/Type    B-Lymphoblastic Leukemia/Lymphoma
|PENDING
|
|
|HD
|
|
|-
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features]]
|Disease
|Lei Zhang, PhD
Michelle Fan (trainee)
|10/10/2025
|12/22/2025
|Pending
|
|
|SK
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]]
|Disease
|Disease
|Yassmine Akkari  Nicolas Millan
|Miguel Gonzalez Mancera, MD
|10/1/2025
|
|
|Pending
|
|
|SK
|
|
|
|
|HD
|B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1
|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO
|PENDING
|
|
|
|
|
|-
|
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]]
|-
|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion
|Disease
|Disease
|Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG  Cancer Category/Type    B-Lymphoblastic Leukemia/Lymphoma
|Miguel Gonzalez Mancera, MD
|10/1/2025
|
|
|Pending
|
|
|SK
|
|
|
|
|HD
|B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3
|
|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO
|PENDING
|
|
|
|
|-
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion]]
|Disease
|Aiko Otsubo, PhD
|10/10/2025
|11/24/2025
|Complete (pending SK review)
|11/11/2025
|SK
|Pending
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations]]
|Disease
|Disease
|Lei Zhang, PhD
|10/10/2025
|12/22/2025
|Pending
|
|
|SK
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma, NOS|B-lymphoblastic leukaemia/lymphoma, NOS]]
|Disease
|Karin Miller, MD
|10/9/2025
|11/24/2025
|Pending
|
|
|SK
|
|
|HD
|
|
|
|
|
|
|
|
|-
|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion
|Disease
|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO
|
|
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|RESOLVE 4th edition ALL-Related NON-WHO entities content
|B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4
B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6
B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements
B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions
B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19)
B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11)
|ISSUE- FIX
Resolve Non-WHO entities
|
|
|
|
|HD
|
|
|
|
|
|
|
|-
|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion
|Disease
|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO
|
|
|
|
|
|
|
|ISSUE - FIX
|HD
|
|
|
|
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty
| ||9/4/2025 sent E-mail reminder|| || ||Shivani Golem (SG)
| ||
|Monoclonal B-cell Lymphocytosis
|Tsigab Bahta Hagos (trainee) / Shashirekha Shetty
|PENDING, 4/30/2024
|
|
|Assigned 12/19/2022 with completion date of 1/19/2023
|-
|-
|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion
|[[HAEM5:Chronic lymphocytic leukaemia/small lymphocytic lymphoma|Chronic lymphocytic leukaemia/small lymphocytic lymphoma]]||Disease||Jaime Nagy, PhD, University of Iowa,
|Disease
 
Renee Eigsti, MD, Pathology Services of Kalamazoo,
 
Honey Reddi, PhD, Belay Diagnostics
| || ||Complete|| ||SG|| ||
|Already converted to 5th edition
|Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD
|
|
|
|
|
|
|-
|[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease||Michael Lack, MD, KUMC (trainee);
Shivani Golem
|7/16/24||9/4/2025 sent E-mail reminder||PENDING|| ||SG|| ||Need new author to update latest content. Prior author cannot update the page.
|Hairy Cell Leukemia
|Snehal Patel, MD, PhD
|Pending WHO 5th e. July 2024
|
|
|
|
|HD
|-
|[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease||Madhu Pantrangi
|4/15/25|| ||9/4/2025 sent E-mail reminder|| ||SG|| ||Need new author to update latest content. Prior author cannot update the page.
|Splenic Marginal Zone Lymphoma
|Snehal Patel, MD, PhD
|Complete
|
|
|
|
|-
|[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease||
| || || || ||SG|| ||Need new author to update latest content. Prior author cannot update the page.
|Splenic Diffuse Red Pulp Small B-cell Lymphoma
|Snehal Patel, MD, PhD
|Complete
|
|
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations
|[[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|Splenic B-cell lymphoma/leukaemia with prominent nucleoli]]
|Disease
|Disease
|
|
Line 979: Line 1,745:
|
|
|
|
|HD
|SG
|
|
|
|Need new author to update latest content. Prior author cannot update the page.
|Hairy Cell Leukemia Variant
|Snehal Patel, MD, PhD
|Complete
|
|
|
|
|-
|-
|B-lymphoblastic leukaemia/lymphoma, NOS
|[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]]
|Disease
|Disease
|
|
|
|
|Sent e-mail to prev authors no reply
|
|
|
|
|SG
|
|
|HD
|Email sent to request to update 2024
|(1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia
|(1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD  Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI)
|Complete
|4/12/2023 by FQR
|
|
|-
|[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]]
|Disease
|
|
|
|
|Sent e-mail to prev authors no reply
|
|
|-
|Monoclonal B-cell lymphocytosis||Disease|| || || || || ||Shivani Golem (SG)
| ||
|
|
|SG
|
|
|-
|Email sent to request to update 2024
|Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease||Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD|| || || || ||SG|| ||
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)
|
|Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG*
 
Department of Pathology and Laboratory Medicine and *Pediatrics, School of Medicine, University of California Irvine (UCI)
|Complete
|4/12/23 by FQR
|
|
|-
|-
|Hairy cell leukaemia||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
|[[HAEM5:Primary cutaneous marginal zone lymphoma|Primary cutaneous marginal zone lymphoma]]
|Disease
|Molly Walkenhorst
|
|
|9/4/2025 sent E-mail reminder
|
|
|-
|Splenic marginal zone lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
|
|
|
|SG
|-
|Splenic diffuse red pulp small B-cell lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
|
|
|
|
|NEW (No Prior)
|Molly Walkenhorst, DO and Shivani Golem, PhD, FACMG
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Splenic B-cell lymphoma/leukaemia with prominent nucleoli
!Disease (5th Edition)
|Disease
!Page Type
|*Snehal Patel, MD, PhD
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
|
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]]
|Disease
|Andrew Ly
|
|
|9/4/2025 sent E-mail reminder
|
|
|
|
Line 1,029: Line 1,830:
|
|
|
|
|
|Nodal Marginal Zone Lymphoma
|Andrew Ly, DO and Shivani Golem, PhD, FACMG
|Complete
|5/28/2021
|
|
|-
|-
|Lymphoplasmacytic lymphoma
|[[HAEM5:Paediatric nodal marginal zone lymphoma|Paediatric nodal marginal zone lymphoma]]
|Disease
|Disease
|Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD  Departments of Pathology, Laboratory Medicine, and *Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI)
|
|
|
|
|
Line 1,041: Line 1,845:
|SG
|SG
|
|
|
|Need new author to update latest content. Prior authors cannot update the page.
|
|Paediatric Nodal Marginal Zone Lymphoma
|* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD
|Complete; Need new author to update latest content. Primary author cannot update the page.
|11/11/2020
|
|
|-
|-
|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue
|[[HAEM5:In situ follicular B-cell neoplasm|In situ follicular B-cell neoplasm]]
|Disease
|Disease
|Rachel D. Burnside, PhD, MBA, FACMGG
|7/28/2023
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024
|Pending
|
|SG
|
|
|
|
|In Situ Follicular Neoplasia
|Rachel D. Burnside, PhD, MBA, FACMGG
|Pending
|
|
|
|
|-
|[[HAEM5:Follicular lymphoma|Follicular lymphoma]]
|Disease
|Rachel D. Burnside, PhD, MBA, FACMGG
|7/28/2023
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024
|Pending
|
|
|SG
|SG
|
|
|
|Author also needs to correlate with 4th edition disease "Testicular Follicular Lymphoma", which is no longer a separate entity
|(1) Follicular Lymphoma + (2) Testicular Follicular Lymphoma
|(1 and 2) Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital  Rachel D. Burnside, PhD, MBA, FACMG, University of Florida
|Pending
|
|
|
|
|-
|-
|Primary cutaneous marginal zone lymphoma
|[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]]
|Disease
|Disease
|Rachel D. Burnside, PhD, MBA, FACMGG
|
|
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024
|
|
|
|
|SG
|
|
|Need new author to update latest content. Prior authors cannot update the page.
|Paediatric-Type Follicular Lymphoma
|*Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG
|Complete; Need new author to update latest content. Primary author  cannot update the page.
|8/16/2020
|
|-
|[[HAEM5:Duodenal-type follicular lymphoma|Duodenal-type follicular lymphoma]]
|Disease
|Rachel D. Burnside, PhD, MBA, FACMGG
|7/28/2023
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside no reply 7/17/
|Pending
|
|
|SG
|SG
|
|
|
|Duodenal-Type Follicular Lymphoma
|No prior content
|
|
|
|
|
|
|-
|-
|Nodal marginal zone lymphoma
|[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]]
|Disease
|Disease
|Andrew Ly, DO and Shivani Golem, PhD, FACMG
|Linlin Gao
|
|
|
|9/4/2025 Sent E-mail to remind
|
|
|
|
Line 1,081: Line 1,926:
|
|
|
|
|
|Primary Cutaneous Follicle Centre Lymphoma
|Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG
|Complete
|09/10/2022
|
|
|-
|-
|Paediatric nodal marginal zone lymphoma
|[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]]
|Disease
|Disease
|* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD
|
|
|
|
|
Line 1,094: Line 1,942:
|
|
|
|
|
|In Situ Mantle Cell Neoplasia
|Rina Kansal, MD; Versiti Blood Center of Wisconsin
|Complete
|7/26/2022
|
|
|-
|-
|In situ follicular B-cell neoplasm
|[[HAEM5:Mantle cell lymphoma|Mantle cell lymphoma]]
|Disease
|Disease
|Rachel D. Burnside, PhD, MBA, FACMGG
|PENDING
|
|
|
|9/4/2025 set E-mail reminder
|
|
|
|
Line 1,107: Line 1,958:
|
|
|
|
|Mantle Cell Lymphoma
|Mahsa Khanlari, MD and  Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas
|Pending
|
|
|
|Target completion date 8/15/20
|-
|-
|Follicular lymphoma
|[[HAEM5:Leukaemic non-nodal mantle cell lymphoma|Leukaemic non-nodal mantle cell lymphoma]]
|Disease
|Disease
|Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital  Rachel D. Burnside, PhD, MBA, FACMG, University of Florida
|Farhan Sami
|
|
|
|9/4/2025 sent E-mail reminder
|
|
|
|
Line 1,120: Line 1,974:
|
|
|
|
|
|NEW (No Prior)
|
|Farhan Sami, MD and Shivani Golem, PhD, FACMG
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|Paediatric-type follicular lymphoma
|[[HAEM5:Transformations of indolent B-cell lymphomas|Transformations of indolent B-cell lymphomas]]
|Disease
|Disease
|*Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG
|Farhan Sami
|
|
|
|9/4/2025 sent E-mail reminder
|
|
|
|
|SG
|SG
|
|
|Include content on chronic myelomonocytic leukemia in transformation and refractory anaemia with excess blasts in transformation
|NEW (No Prior)
|Farhan Sami, MD and Shivani Golem, PhD, FACMG
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease||
| || || || ||GC|| ||
|Diffuse Large B-cell Lymphoma, Not Otherwise Specified
|Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center
|Pending
|
|
|
|Requested to update 14022022
|-
|[[HAEM5:T-cell/histiocyte-rich large B-cell lymphoma|T-cell/histiocyte-rich large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland
|5/6/2025||8/6/2025 Emailed 9/4/2025 to remind|| || ||GC|| ||
|High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland
|Complete
|24/02/2022
|
|
|-
|-
|Duodenal-type follicular lymphoma
|[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease||
|Disease
| || || || ||GC|| ||
|ALK-Positive Large B-cell Lymphoma
|Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)
|
|
|
|
|Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23
|-
|[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease||
| || || || ||GC|| ||
|Large B-cell Lymphoma with IRF4 Rearrangement
|Afia Hasnain, MBBS, PhD
|Complete
|5/26/2021. Emailed 5/7//2025, no reply
|
|
|-
|[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease||
| || || || ||GC|| ||
|Burkitt-Like Lymphoma with 11q Aberration
|Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina
|Complete
|27/01/2022  Emailed 5/7//2025, no reply
|
|
|-
|[[HAEM5:Lymphomatoid granulomatosis|Lymphomatoid granulomatosis]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease||Fnu Monika (trainee);
Andrew Siref as mentor
|3/22/24|| ||Pending|| ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Diffuse large B-cell lymphoma associated with chronic inflammation|Diffuse large B-cell lymphoma associated with chronic inflammation]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease||
| || || || ||GC|| ||Note: previously a subset DLBCL assoc with chronic inflam
|Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Fluid overload-associated large B-cell lymphoma|Fluid overload-associated large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease||
| || || || ||GC|| ||
|Plasmablastic Lymphoma
|Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
|Complete
|28/03/2022
|
|-
|[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease||Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital
|6/28/2025
|9/28/2025 Emailed 9/4/2025 to remind.|| || ||GC|| ||
|(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS
|(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital
|(1) Pending + (2) Complete
|(1) Not ready + (2) 03/28/22
|For "Diffuse Large B-cell Lymphoma, Not Otherwise Specified" page from Ash, Greg requested to update 14022022
|-
|[[HAEM5:Primary cutaneous diffuse large B-cell lymphoma, leg type|Primary cutaneous diffuse large B-cell lymphoma, leg type]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland
|5/6/2025
|8/6/2025 Emailed 9/4/2025 to remind
| || ||GC|| ||
|Intravascular Large B-cell Lymphoma
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy
|Complete
|9/1/22
|Emailed 28/3/2022 for progress update
|-
|[[HAEM5:Primary mediastinal large B-cell lymphoma|Primary mediastinal large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Mediastinal grey zone lymphoma|Mediastinal grey zone lymphoma]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease||
| || || || ||GC|| ||
|High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)
|Aiko Otsubo, PhD, Indiana University, Holli Drendel
|Complete
|16/11/2021 Emailed 5/6/2025, no reply
|
|
|SG
|-
|[[HAEM5:Burkitt lymphoma|Burkitt lymphoma]]||Disease||
| || || || ||GC|| ||
|Burkitt Lymphoma
|Becky Leung, MBBS (Hons), BSc, Pathology Queensland
|Complete
|28/06/2021 Emailed 5/6/2025, no reply
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Primary effusion lymphoma|Primary effusion lymphoma]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:KSHV/HHV8-positive diffuse large B-cell lymphoma|KSHV/HHV8-positive diffuse large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:KSHV/HHV8-positive germinotropic lymphoproliferative disorder|KSHV/HHV8-positive germinotropic lymphoproliferative disorder]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Hyperplasias arising in immune deficiency/dysregulation|Hyperplasias arising in immune deficiency/dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing non-destructive post-transplant lymphoproliferative disorders, among others"). "Non-Destructive Post-Transplant Lymphoproliferative Disorders" was a HAME4 page but no content.  What are "among others" from HAEM4 to see if we need to pull prior content into 5th edition page.|| || || || ||GC|| ||
|
|
|
|
|
|
|-
|Primary cutaneous follicle centre lymphoma
|Disease
|Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG
|
|
|
|
|-
|[[HAEM5:Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Polymorphic Post-Transplant Lymphoproliferative Disorders]].
Note: encompassing polymorphic PTLD, other iatrogenic immunodef-assoc lympho disorders, among others)"
| || || || ||GC|| ||
|Polymorphic Post-Transplant Lymphoproliferative Disorders
|Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories  Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)
|Completed
|26/4/2022
|
|
|-
|[[HAEM5:EBV-positive mucocutaneous ulcer|EBV-positive mucocutaneous ulcer]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Lymphomas arising in immune deficiency / dysregulation|Lymphomas arising in immune deficiency / dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing monomorphic PTLD, classic HL PTLD, lymphomas assoc with HIV infection, among others"|| || || || ||GC|| ||
|
|
|SG
|
|
|
|
Line 1,162: Line 2,244:
|
|
|-
|-
|In situ mantle cell neoplasm
|[[HAEM5:Inborn error of immunity-associated lymphoid proliferations and lymphomas|Inborn error of immunity-associated lymphoid proliferations and lymphomas]]||Disease||FIX ISSUE! (on 5th edition page instructions say "Editor said this overview page is a match. [Immunodeficiency-Associated Lymphoproliferative Disorders] [Lymphoproliferative diseases associated with primary immune disorders]") - last link name above is not a known page in haem4 or haem5.|| || || || ||GC|| ||
|Disease
|Rina Kansal, MD; Versiti Blood Center of Wisconsin
|
|
|
|
|
|
|SG
|
|
|
|
|
|
|-
|[[HAEM5:Classic Hodgkin lymphoma|Classic Hodgkin lymphoma]]||Disease||Xiaolin Hu
|5/7/2025
|8/7/2025 Reminder email sent 9/4/2025|| ||
|GC|| ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma
|(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma
|(1) Patricia V. Hernandez, M.D., Washington University School of Medicine and Holli Drendel + (2) Xiaolin Hu, PhD, Sema4 OpCo Inc. + (3 and 4) Patricia V. Hernandez
|Pending + Completed (03/21/22)
|Not completed for checking (1, 3 and 4) + 03/21/22 (2)
|
|
|-
|-
|Mantle cell lymphoma
|[[HAEM5:Nodular lymphocyte predominant Hodgkin lymphoma|Nodular lymphocyte predominant Hodgkin lymphoma]]||Disease||Muhammad Zulfiqar, MD
|7/4/2025
|10/4/2025 Reminder email sent 9/4/2025||Pending|| ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Cold agglutinin disease|Cold agglutinin disease]]
|Disease
|Disease
|* Mahsa Khanlari, MD * Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas
|
|
|
|
|
Line 1,185: Line 2,296:
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:IgM monoclonal gammopathy of undetermined significance|IgM monoclonal gammopathy of undetermined significance]]||Disease|| || || || || ||SG|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Non-IgM monoclonal gammopathy of undetermined significance|Non-IgM monoclonal gammopathy of undetermined significance]]||Disease|| || || || || ||SG|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Monoclonal gammopathy of renal significance|Monoclonal gammopathy of renal significance]]||Disease|| || || || || ||SG
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Immunoglobulin-related (AL) amyloidosis|Immunoglobulin-related (AL) amyloidosis]]||Disease||
| || || || ||SG
| ||
|Primary Amyloidosis
|Heather E. Williams, PhD, MS, PgD, ErCLG
|?PENDING<br />
|
|
|
|
|-
|-
|Leukaemic non-nodal mantle cell lymphoma
|[[HAEM5:Monoclonal immunoglobulin deposition disease|Monoclonal immunoglobulin deposition disease]]||Disease||
|Disease
| || || || ||SG
|<br />
| ||
|Light Chain and Heavy Chain Deposition Disease
|Chen Yang, MD, PhD, University of Michigan
|Complete
|10/15/2022
|
|
|-
|[[HAEM5:Mu heavy chain disease|Mu heavy chain disease]]||Disease|| || || || || ||SG
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Gamma heavy chain disease|Gamma heavy chain disease]]||Disease||
| || || || ||SG
| ||
|Gamma Heavy Chain Disease
|Manisha Brahmbhatt-Sutariya  Asst. Professor, Dept. of Pathology and Human Anatomy  Technical Supervisor, Clinical Genetics Laboratory  Loma Linda University, Medical Center, CA
|Complete
|5/26/2021
|
|
|-
|[[HAEM5:Alpha heavy chain disease|Alpha heavy chain disease]]||Disease|| || || || || ||SG
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Plasmacytoma|Plasmacytoma]]||Disease||
| || || ||
|SG
| ||author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga)
|NEW (No Prior) - no content on version 4 page "Plasmacytoma' originally assigned to Zhenya Tang
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||Huan Mo;
Zhenya Tang
|4/14/25||7/14/25
9/4/2025 Sent E-mail reminder to Dr. Tang
|Pending|| ||SG
| ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page
|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants
|(1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG
|Pending
|
|
|
|
|-
|[[HAEM5:Plasma cell neoplasms with associated paraneoplastic syndrome|Plasma cell neoplasms with associated paraneoplastic syndrome]]||Disease||PENDING
| ||9/4/2025 E-mail sent to Dr. Senaratne
| ||
|SG
|SG
| ||Note: author needs to include POEMS, TEMPI, and look for AESOP content
|(1) POEMS Syndrome + (2) TEMPI Syndrome
|(1 and 2) Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD
|?PENDING
|
|
|
|
|
|
|-
|-
|Transformations of indolent B-cell lymphomas
|Disease (5th Edition)
|Page Type
|Author (5th Edition) (Note: please indicate trainees in parenthesis)
|Date Assigned to Author (5th Edition)
|Target Completion Date (5th Edition)
|Content Status (5th Edition) (Pending or Complete)
|Date Completed by Author (5th Edition)
|Associate Editor
|Date of Last Editor Review (5th Edition)
|Notes (5th Edition)
|Correlated Prior Disease Name (4th Edition)
|Correlated Prior Author (4th Edition)
|Prior Content Status (4th Edition) (Pending or Complete)
|Prior Date of Last Editor Review (4th Edition)
|Prior Notes (4th Edition)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
| colspan="15" |
====CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)====
|-
|[[HAEM5:Kikuchi-Fujimoto disease|Kikuchi-Fujimoto disease]]||Disease|| Sumire Kitahara, MD|| || || '''Complete'''|| 11/6/2025||Sumi Kitahara (SK)
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Autoimmune lymphoproliferative syndrome|Autoimmune lymphoproliferative syndrome]]||Disease||Aviv Oren, MD (trainee);
Karin Miller, MD
|3/25/2024
| ||Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Indolent T-lymphoblastic proliferation|Indolent T-lymphoblastic proliferation]]||Disease|| || || || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:T-lymphoblastic leukaemia / lymphoma, NOS|T-lymphoblastic leukaemia / lymphoma, NOS]]||Disease|| || || || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Early T-precursor lymphoblastic leukaemia / lymphoma|Early T-precursor lymphoblastic leukaemia / lymphoma]]
|Disease
|Disease
|Fei Yang, MD
|
|
|
|
|
|
|
|
|
|SK
|SG
|
|
|
|
|Early T-Cell Precursor Lymphoblastic Leukemia
|Fei Yang, MD, FACMG, Kaiser Permanente Northwest
|Pending
|
|
|
|
|-
|-
|Diffuse large B-cell lymphoma, NOS||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
|[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]]
|
|Disease
|Parastou Tizro, MD;
Celeste Eno, PhD; Sumire Kitahara, MD
|9/23/2025
|11/4/2025
|'''Complete'''
|11/4/2025
|SK
|11/6/2025
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|T-cell/histiocyte-rich large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Nicolas LaScala (trainee);
Michelle Don, MD, MS
|9/24/2025
|12/9/2025
|Pending
| ||SK|| ||
|T-cell Large Granular Lymphocytic Leukemia
|Michelle Don, MD, MS
|Pending
|
|
|
|
|-
|-
|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
|[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Hailee St. Louis (trainee);
Michelle Don, MD, MS
|9/24/2025
|12/9/2025
|'''Complete'''
| 12/17/2025||SK|| 1/6/2026||
|Chronic Lymphoproliferative Disorder of NK Cells
|Michelle Don, MD
|Pending
|
|
|
|
|-
|-
|ALK-positive large B-cell lymphoma||Disease||Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)|| || || || ||GC|| ||
|[[HAEM5:Adult T-cell leukaemia/lymphoma|Adult T-cell leukaemia/lymphoma]]||Disease||Sumire Kitahara, MD
|9/23/2025
|11/30/2025
|Pending
| ||SK|| ||
|Adult T-cell Leukemia/Lymphoma
|Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center
|?Pending
|
|
|
|
|-
|-
|Large B-cell lymphoma with IRF4 rearrangement||Disease||*Afia Hasnain, MBBS, PhD|| || || || ||GC|| ||
|[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD
|3/22/2024
|follow-up needed
| || ||SK|| ||
|Sézary Syndrome
|Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina
|Pending
|
|
|
|
|-
|-
|High grade B-cell lymphoma with 11q aberrations||Disease||Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina|| || || || ||GC|| ||
|[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease||Shashirekha Shetty, PhD
|10/15/2025||1/19/2026
|Pending
| ||SK|| ||
|Aggressive NK-cell Leukemia
|Shanelle De Lancy, MD, Shashirekha Shetty, PhD
|?Pending
|
|
|
|
|-
|-
|Lymphomatoid granulomatosis||Disease|| || || || || ||GC|| ||
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Ian King, PhD
|1/6/2026
| 2/3/2026||
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder]]||Disease||Ahmed Eladely (trainee);
 
Andrew Siref, MD
|10/14/2025
|11/24/2025
|'''Complete'''
| 12/29/2025||SK|| 1/6/2026||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD
|3/22/2024
|follow-up needed|| || ||SK|| ||
|Mycosis Fungoides
|Jane Scribner, MD and Daynna J. Wolff, PhD
|Pending
|
|
|
|
|-
|-
|EBV-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis]]||Disease||Rabail Aslam, MD (fellow);
Shashirekha Shetty, PhD
|7/1/2024
|follow-up needed
|
|
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||Rabail Aslam, MD (fellow);
Shashirekha Shetty, PhD
|7/1/2024||follow-up needed
|
|
|-
| ||SK|| ||
|Diffuse large B-cell lymphoma associated with chronic inflammation||Disease|| || || || || ||GC|| ||
|Primary Cutaneous Anaplastic Large Cell Lymphoma
|Theresa Spivey, MD, Shashirekha Shetty, PhD
|Pending
|
|
|
|
|-
|-
|Fibrin-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Ian King, PhD
Katelyn Swanson, DO (trainee)
|11/19/2025
|12/19/2025
|'''Complete'''
| 1/6/2026||SK|| 1/6/2026||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee);
Sumire Kitahara, MD
|6/30/2024
|11/9/2025
|Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma]]||Disease||Ahmed Eladely (trainee);
 
Andrew Siref, MD
|10/14/2025||11/24/2025
|'''Complete'''
| 12/29/2025||SK|| 1/6/2026||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Primary cutaneous peripheral T-cell lymphoma, NOS|Primary cutaneous peripheral T-cell lymphoma, NOS]]||Disease|| || || || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease||
| || || || ||SK|| ||
|Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
|Pending
|
|
|
|
|-
|-
|Fluid overload-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|[[HAEM5:Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract]]||Disease|| || || || || ||SK|| ||
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee);
Andrew Siref, MD
|10/14/2025
| ||Pending|| ||SK|| ||
|Enteropathy-Associated T-cell Lymphoma
|*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD
|Complete
|1/21/2021
|
|
|-
|-
|Plasmablastic lymphoma||Disease||Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||GC|| ||
|[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee);
Andrew Siref, MD
|10/14/2025
| ||Pending|| ||SK|| ||
|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
|Pending
|
|
|
|
|-
|-
|Primary large B-cell lymphoma of immune-privileged sites||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
|[[HAEM5:Intestinal T-cell lymphoma, NOS|Intestinal T-cell lymphoma, NOS]]||Disease||
| || || || ||SK|| ||
|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)
|Derick Okwan MD, PhD (Stanford)  Sumire Kitahara MD (Cedars-Sinai)
|Complete
|9/26/2022
|
|
|-
|[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Forough Sargolzaeiaval (trainee);
Michelle Don, MD, MS
|9/24/2025
|11/9/2025
|'''Complete'''
|12/17/2025
|SK||1/6/2026||
|Hepatosplenic T-cell Lymphoma
|Michelle Don, MD, MS
|Complete
|1/21/2021
|
|
|-
|-
|Primary cutaneous diffuse large B-cell lymphoma, leg type||Disease|| || || || || ||GC|| ||
|[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee);
 
Sumire Kitahara, MD
|6/6/24|| ||
| ||SK|| ||
|Anaplastic Large Cell Lymphoma, ALK-Positive
|Miguel Gonzalez Mancera, MD
 
Sumire Kitahara, MD
 
Cedars-Sinai, Los Angeles, CA
|Complete
|09/23/2022
|
|
|-
|[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee);
Sumire Kitahara, MD
|6/6/24|| ||
| ||SK|| ||
|Anaplastic Large Cell Lymphoma, ALK-Negative
|Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA
|Complete
|09/23/2022
|
|
|-
|-
|Intravascular large B-cell lymphoma||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
|[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||Lynne Abruzzo, MD, PhD
|9/22/2025
|1/1/2026
|Pending|| ||SK|| ||
|Breast Implant-Associated Anaplastic Large Cell Lymphoma
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center
|Pending
|
|
|
|
|-
|-
|Primary mediastinal large B-cell lymphoma||Disease|| || || || || ||GC|| ||
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023
|follow-up needed
| || ||SK|| ||prior authors not available
|Angioimmunoblastic T-cell Lymphoma
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG
|Pending
|
|
|
|
|-
|-
|Mediastinal grey zone lymphoma||Disease|| || || || || ||GC|| ||
|[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023
|
|follow-up needed
|
| || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|High-grade B-cell lymphoma, NOS||Disease||Aiko Otsubo, PhD, Indiana University|| || || || ||GC|| ||
|[[HAEM5:Nodal TFH cell lymphoma, NOS|Nodal TFH cell lymphoma, NOS]]||Disease||
| || || || ||SK|| ||
|Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype
|Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD
|Pending
|
|
|
|
|-
|-
|Burkitt lymphoma||Disease||Becky Leung, MBBS (Hons), BSc, Pathology Queensland|| || || || ||GC|| ||
|[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD
|
|10/14/2025
|
|12/3/2025
|Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee);
Andrew Siref, MD
|10/14/2025|| ||Pending|| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Primary effusion lymphoma||Disease|| || || || || ||GC|| ||
|[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Maryam Mehdiopour Dalivand (trainee); Ian King, PhD
|
|1/6/2026
|
| 2/3/2026||Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|[[HAEM5:Severe mosquito bite allergy|Severe mosquito bite allergy]]||Disease|| || || || || ||SK|| ||
|
|NEW (No Prior)
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC|| ||
|[[HAEM5:Hydroa vacciniforme lymphoproliferative disorder|Hydroa vacciniforme lymphoproliferative disorder]]||Disease|| || || || || ||SK|| ||
|
|NEW (No Prior)
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Hyperplasias arising in immune deficiency/dysregulation||Disease|| || || || || ||GC|| ||
|[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD
|
|3/25/2024
|
| 11/17/2025||Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories  Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)|| || || || ||GC|| ||
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD
|
|3/25/2024
| 11/17/2025||Pending
| ||SK|| ||prior authors not available
|Systemic EBV-Positive T-cell Lymphoma of Childhood
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
|Complete
|11/21/2021
|
|
|-
|-
|EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC|| ||
!Disease (5th Edition)
|
!Page Type
|
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|Lymphomas arising in immune deficiency / dysregulation||Disease|| || || || || ||GC|| ||
|
|
====CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)====
|
|
|-
----<br />
|Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease|| || || || || ||GC|| ||
|
|
----<br />
|
|
|-
----<br />
|Classic Hodgkin lymphoma||Disease||Patricia V. Hernandez, M.D., Washington University School of Medicine|| || || || ||GC|| ||
|
|
----<br />
|
|
|-
----<br />
|Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC|| ||
|
|
----<br />
|
|
|-
----<br />
|Cold agglutinin disease
|Disease
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
|SG
----<br />
|
----<br />
|
|
----<br />
|-
|[[HAEM5:Follicular dendritic cell sarcoma|Follicular dendritic cell sarcoma]]
|Disease
|
|
|
|
|
|
|-
|IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
|
|
|
|
|-
|GC
|Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
|
|
|
|
|-
|Follicular Dendritic Cell Sarcoma
|Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG
|Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG
| ||
|?Pending
|
|
|
|
|-
|-
|Immunoglobulin-related (AL) amyloidosis||Disease||Heather E. Williams, PhD, MS, PgD, ErCLG|| || || || ||SG
|[[HAEM5:EBV-positive inflammatory follicular dendritic cell sarcoma|EBV-positive inflammatory follicular dendritic cell sarcoma]]
| ||
|Disease
|
|
|
|
|-
|Monoclonal immunoglobulin deposition disease||Disease||Chen Yang, MD, PhD, University of Michigan|| || || || ||SG
| ||
|
|
|
|
|-
|Mu heavy chain disease||Disease|| || || || || ||SG
| ||
|
|
|GC
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Gamma heavy chain disease||Disease||Manisha Brahmbhatt-Sutariya  Asst. Professor, Dept. of Pathology and Human Anatomy  Technical Supervisor, Clinical Genetics Laboratory  Loma Linda University, Medical Center, CA|| || || || ||SG
|[[HAEM5:Fibroblastic reticular cell tumour|Fibroblastic reticular cell tumour]]
| ||
|Disease
|
|
|
|
|-
|Alpha heavy chain disease||Disease|| || || || || ||SG
| ||
|
|
|
|
|-
|Plasmacytoma||Disease|| || || || || ||SG
| ||
|
|
|
|GC
|-
|Plasma cell myeloma / multiple myeloma||Disease||*Huan Mo, MD, MS *Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SG
| ||
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD|| || || || ||SG
|[[HAEM5:Intranodal palisaded myofibroblastoma|Intranodal palisaded myofibroblastoma]]
| ||
|Disease
|
|
|
|
|-
|CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
|
|
----<br />
|
|
----<br />
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Littoral cell angioma|Littoral cell angioma]]
|Disease
|
|
|
|
Line 1,409: Line 3,001:
|
|
|
|
|
|GC
|-
|Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK)
| ||
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SK|| ||
|[[HAEM5:Splenic hamartoma|Splenic hamartoma]]
|Disease
|
|
|
|
|-
|Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK|| ||
|
|
|
|
|-
|
|T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||HD|| ||
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Early T-precursor lymphoblastic leukaemia / lymphoma
|[[HAEM5:Sclerosing angiomatoid nodular transformation (SANT) of spleen|Sclerosing angiomatoid nodular transformation (SANT) of spleen]]
|Disease
|Disease
|Fei Yang, MD, FACMG, Kaiser Permanente Northwest
|
|
|
|
|
|
|
|HD
|
|
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|T-prolymphocytic leukaemia
|Disease
|
|
====CHAPTER 7 (GENETIC TUMOUR SYNDROMES)====
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
|SK
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
|-
----<br />
|T-large granular lymphocytic leukaemia||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
|
|
----<br />
|
|
|-
----<br />
|NK-large granular lymphocytic leukaemia||Disease||Michelle Don, MD|| || || || ||SK|| ||
|
|
----<br />
|
|
|-
----<br />
|Adult T-cell leukaemia/lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center|| || || || ||SK|| ||
|
|
|-
|Sezary syndrome||Disease||Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina|| || || || ||SK|| ||
|
|
|-
|Aggressive NK-cell leukaemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
|
|
|-
|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
|
|
|-
|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
|
|
|-
|Mycosis fungoides||Disease||Jane Scribner, MD and Daynna J. Wolff, PhD|| || || || ||SK|| ||
|
|
|-
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SK|| ||
|
|
|-
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
|
|
|-
|Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|-
|Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|-
|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|-
|Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
|
|
|-
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
|
|
|-
|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK|| ||
|
|
|-
|Enteropathy-associated T-cell lymphoma||Disease||*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD|| || || || ||SK|| ||
|
|
|-
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
|
|
|-
|Intestinal T-cell lymphoma, NOS||Disease||Derick Okwan MD, PhD (Stanford Medicine, CA)  Sumire Kitahara MD (Cedars-Sinai, CA)|| || || || ||SK|| ||
|
|
|-
|Hepatosplenic T-cell lymphoma||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
|
|
|-
|ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|-
|ALK-negative anaplastic large cell lymphoma||Disease||Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA|| || || || ||SK|| ||
|
|
|-
|Breast implant-associated anaplastic large cell lymphoma||Disease||Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center|| || || || ||SK|| ||
|
|
|-
|Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG|| || || || ||SK|| ||
|
|
|-
|Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SK|| ||
|
|
|-
|Nodal TFH cell lymphoma, NOS||Disease||Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD|| || || || ||SK|| ||
|
|
|-
|Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
|
|
|-
|EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|-
|Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|-
|Severe mosquito bite allergy||Disease|| || || || || ||SK|| ||
|
|
|-
|Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
|
|
|-
|Systemic chronic active EBV disease||Disease|| || || || || ||SK|| ||
|
|
|-
|Systemic EBV-positive T-cell lymphoma of childhood||Disease||*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA|| || || || ||SK|| ||
|
|
|-
|CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)
|
----<br />
|
----<br />
|
|
|
|
|
|
|
|
|
|-
|Follicular dendritic cell sarcoma
|Disease
|Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG
|
|
|
|
|GC
|
|
|
|
|-
|EBV-positive inflammatory follicular dendritic cell sarcoma
|Disease
|
|
|
|
|
|GC
|
|
|
|
|-
|Fibroblastic reticular cell tumour
|Disease
|
|
|
|
|
|GC
|
|
|
|
|-
|Intranodal palisaded myofibroblastoma
|Disease
|
|
|
|
|
|GC
|
|
|
|
|-
|Littoral cell angioma
|Disease
|
|
|
|
|
|GC
|
|
|
|
|-
|Splenic hamartoma
|Disease
|
|
|
|
|
|GC
|
|
|
|
|-
|Sclerosing angiomatoid nodular transformation (SANT) of spleen
|Disease
|
|
|
|
|
|GC
|
|
|
|
|-
|CHAPTER 7 (GENETIC TUMOUR SYNDROMES)
|
|
----<br />
----<br />
|
|
----<br />
----<br />
|
|
|
|
|
|
|
|
|
|-
|-
|Fanconi anaemia||Disease|| || || || || ||NA|| ||
|[[HAEM5:Fanconi anaemia|Fanconi anaemia]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]]
|
|N/A||N/A
|
|N/A
|N/A
|N/A
|N/A
|N/A
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Bloom syndrome||Disease|| || || || || ||NA|| ||
|[[HAEM5:Bloom syndrome|Bloom syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA|| ||
|[[HAEM5:Ataxia-telangiectasia syndrome|Ataxia-telangiectasia syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]]||N/A||N/A||N/A||N/A||N/A||N/A||N/A
|
|NEW (No Prior)
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|RASopathies||Disease|| || || || || ||NA|| ||
|[[HAEM5:RASopathies|RASopathies]]||Disease|| || || || || ||NA|| ||
|
|NEW (No Prior)
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|}
|}
Retrieved from "https://test.ccga.io/index.php/HAEM5:Volunteer_Assignments_and_Opportunities"